BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32989221)

  • 1. Glucocorticoids induce differentiation and chemoresistance in ovarian cancer by promoting ROR1-mediated stemness.
    Karvonen H; Arjama M; Kaleva L; Niininen W; Barker H; Koivisto-Korander R; Tapper J; Pakarinen P; Lassus H; Loukovaara M; Bützow R; Kallioniemi O; Murumägi A; Ungureanu D
    Cell Death Dis; 2020 Sep; 11(9):790. PubMed ID: 32989221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Mechanisms Associated with ROR1-Mediated Drug Resistance: Crosstalk with Hippo-YAP/TAZ and BMI-1 Pathways.
    Karvonen H; Barker H; Kaleva L; Niininen W; Ungureanu D
    Cells; 2019 Aug; 8(8):. PubMed ID: 31382410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody.
    Zhang S; Zhang H; Ghia EM; Huang J; Wu L; Zhang J; Lam S; Lei Y; He J; Cui B; Widhopf GF; Yu J; Schwab R; Messer K; Jiang W; Parker BA; Carson DA; Kipps TJ
    Proc Natl Acad Sci U S A; 2019 Jan; 116(4):1370-1377. PubMed ID: 30622177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy.
    Zhang S; Cui B; Lai H; Liu G; Ghia EM; Widhopf GF; Zhang Z; Wu CC; Chen L; Wu R; Schwab R; Carson DA; Kipps TJ
    Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17266-71. PubMed ID: 25411317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1.
    Islam SS; Uddin M; Noman ASM; Akter H; Dity NJ; Basiruzzman M; Uddin F; Ahsan J; Annoor S; Alaiya AA; Al-Alwan M; Yeger H; Farhat WA
    EBioMedicine; 2019 May; 43():211-224. PubMed ID: 31085100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of CD133-Sustained Chemoresistant Cancer Stem-Like Cells in Human Ovarian Carcinoma.
    Liu CL; Chen YJ; Fan MH; Liao YJ; Mao TL
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
    Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
    J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion.
    Henry C; Llamosas E; Knipprath-Meszaros A; Schoetzau A; Obermann E; Fuenfschilling M; Caduff R; Fink D; Hacker N; Ward R; Heinzelmann-Schwarz V; Ford C
    Oncotarget; 2015 Nov; 6(37):40310-26. PubMed ID: 26515598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion.
    Koren Carmi Y; Mahmoud H; Khamaisi H; Adawi R; Gopas J; Mahajna J
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32906729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer.
    Feng L; Shen F; Zhou J; Li Y; Jiang R; Chen Y
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32190895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of ROR1 in Chemoresistance and EMT in Endometrial Cancer Cells.
    Lee KJ; Kim NH; Kim HS; Kim Y; Lee JJ; Kim JH; Cho HY; Jeong SY; Park ST
    Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241228
    [No Abstract]   [Full Text] [Related]  

  • 12. Chromatin target of protein arginine methyltransferase regulates invasion, chemoresistance, and stemness in epithelial ovarian cancer.
    Feng X; Li L; Wang L; Luo S; Bai X
    Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30910850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting.
    Karvonen H; Perttilä R; Niininen W; Hautanen V; Barker H; Murumägi A; Heckman CA; Ungureanu D
    Oncogene; 2019 Apr; 38(17):3288-3300. PubMed ID: 30631148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ROR1 Expression and Its Functional Significance in Hepatocellular Carcinoma Cells.
    Cetin M; Odabas G; Douglas LR; Duriez PJ; Balcik-Ercin P; Yalim-Camci I; Sayan AE; Yagci T
    Cells; 2019 Mar; 8(3):. PubMed ID: 30832318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting ROR1 inhibits the self-renewal and invasive ability of glioblastoma stem cells.
    Jung EH; Lee HN; Han GY; Kim MJ; Kim CW
    Cell Biochem Funct; 2016 Apr; 34(3):149-57. PubMed ID: 26923195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity.
    Rumman M; Buck S; Polin L; Dzinic S; Boerner J; Winer IS
    Cancer Med; 2021 May; 10(10):3373-3387. PubMed ID: 33932119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DEAD-Box Helicase 4 (Ddx4)
    D'Oronzo S; Silvestris E; Lovero D; Cafforio P; Duda L; Cormio G; Paradiso A; Palmirotta R; Silvestris F
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32847044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer.
    Nacarelli T; Fukumoto T; Zundell JA; Fatkhutdinov N; Jean S; Cadungog MG; Borowsky ME; Zhang R
    Cancer Res; 2020 Feb; 80(4):890-900. PubMed ID: 31857293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian Cancer Stem Cells with High ROR1 Expression Serve as a New Prophylactic Vaccine for Ovarian Cancer.
    Wu D; Yu X; Wang J; Hui X; Zhang Y; Cai Y; Ren M; Guo M; Zhao F; Dou J
    J Immunol Res; 2019; 2019():9394615. PubMed ID: 31008116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
    Li H; Zhang W; Niu C; Lin C; Wu X; Jian Y; Li Y; Ye L; Dai Y; Ouyang Y; Chen J; Qiu J; Song L; Zhang Y
    Int J Cancer; 2019 Oct; 145(7):1921-1934. PubMed ID: 30895619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.